1 Title: Hepatitis E in Kathmandu Valley: Insights from a Representative Longitudinal

2 Serosurvey

3

4 Authors

- 5 Nishan Katuwal^{1,2}, Melina Thapa¹, Sony Shrestha¹, Krista Vaidya^{1,3}, Isaac I Bogoch⁴,
- 6 Jason Andrews⁵, Rajeev Shrestha^{1,2}, Dipesh Tamrakar^{1,2,6¥}, Kristen Aiemjoy^{3,7¥*}
- 7
- 8 1 Research and Development Division, Dhulikhel Hospital, Kathmandu University
- 9 Hospital, Nepal
- 10 2 Center for Infectious Disease Research and Surveillance, Dhulikhel Hospital,
- 11 Kathmandu University Hospital, Nepal
- 12 3 Division of Epidemiology, Department of Public Health Sciences, University of California
- 13 Davis School of Medicine, USA
- 14 4 Department of Medicine, University of Toronto, Canada
- 15 5 Division of Infectious Diseases and Geographic Medicine, Stanford University School
- 16 of Medicine, USA
- 17 6 Department of Community Medicine, Kathmandu University School of Medical
- 18 Sciences, Nepal
- 19 7 Department of Microbiology and Immunology, Mahidol University Faculty of Tropical
- 20 Medicine, Thailand
- 21
- 22 ***Corresponding Author:**
- 23 Dr. Kristen Aiemjoy
- 24 Email: kaiemjoy@ucdavis.edu
- 25
- 26 ¥: equal contribution
- 27
- 28
- 29

30 ABSTRACT

31

32 Hepatitis-E virus (HEV), an etiologic agent of acute inflammatory liver disease, is a significant cause of morbidity and mortality in South Asia. HEV is considered endemic in 33 34 Nepal; but data on population-level infection transmission is sparse. We conducted a 35 representative longitudinal serologic study between February 2019 and April 2021 in 36 urban and peri-urban areas of central Nepal to characterize community-level HEV 37 transmission. Individuals were followed up to four times, during which capillary blood samples were collected on dried blood spots and tested for anti-HEV immunoglobulin-G 38 39 antibodies. Analyzing 2513 dried blood samples from 923 participants aged 0-25 years. 40 we found a seroprevalence of 4.8% and a seroincidence rate of 10.9 per 1000 person-41 years. Notably, young adults, including women of childbearing age, faced the highest 42 incidence of infection. Geospatial analysis identified potential HEV clusters in Kavre and 43 Kathmandu districts, emphasizing the need for targeted interventions. Water source 44 played a crucial role in HEV transmission, with individuals consuming surface water facing 45 the highest risk of seroconversion. Our findings underscore the endemic nature of HEV 46 in Nepal, emphasizing the importance of safe water practices and potential vaccination 47 strategies for high-risk groups. 48

- 49
- 50
- 51
- 52
- 53
- 54
- 55

57 BACKGROUND

Hepatitis E Virus (HEV), first identified in 1983, has emerged as the leading cause of acute clinical hepatitis in South Asia (1). The overall mortality rate associated with HEV is 1–4% (2). Immunocompromised individuals and pregnant women face the highest risk for complications and death, with mortality rates reaching up to 20% among pregnant women in their third trimester (3). The virus is primarily transmitted through food and water contaminated with infected fecal material, disproportionately affecting individuals in locations lacking improved sanitation systems (2).

HEV is estimated to cause approximately 20 million new infections annually, leading to around 3.3 million symptomatic cases and 70,000 deaths (4). However, these figures may be underestimates due to limited surveillance capacity and suboptimal access to laboratory diagnostics, which often leave many infections, especially pauci-symptomatic and subclinical cases, undetected and under-reported (5).

70 Sero-epidemiology provides a valuable tool to augment clinical surveillance of HEV, 71 particularly when diagnostics and reporting systems are limited (6). Population-level sero-72 responses also offers insights into exposure that are not biased by access to health care 73 and care-seeking behaviors (7). Despite the existence of four recognized HEV genotypes. 74 the antibody responses they elicit are similar (2). IgG antibody responses peak 2-6 weeks 75 post-infection (8,9) then start to decay. A study of confirmed HEV patients in Nepal found 76 that IgG responses decayed substantially in the first 6 months but remained elevated 77 above a seropositivity threshold for at least 14 months (10).

78 Nepal, considered endemic for hepatitis E virus, has experienced repeated outbreaks of 79 HEV with sporadic cases of acute hepatitis between such outbreaks (11). A study among 80 individuals seeking orthopedic care in Kathmandu between 2010 and 2012 found an IgG 81 seroprevalence of 47.1% (12). Among healthy blood donors in Kathmandu in 2014, the 82 age-adjusted seroprevalence of HEV was 3.2% for IgM and 8.3% for IgG (13). A study 83 conducted after the 2015 earthquake among blood donors residing in earthquake-84 affected areas found a HEV seroprevalence of 3.2% for IgM and 41.9% for IgG (14). Most 85 previous seroprevalence studies were conducted using convenience samples (healthy

blood donors or individuals seeking care in a hospital setting), and it is unknown how well
these estimates represent the general population .

To meet this gap, we performed a longitudinal HEV serosurvey among a geographically random population-based sample of children and young adults residing in Kathmandu and Kavre districts. The aim was to gain a better understanding of the geographic distribution of HEV, characterize the incidence, and investigate risk factors related to exposure.

93 METHODS

94 **Overview**

95 We conducted a representative, population-based longitudinal cohort study in urban 96 (Kathmandu) and peri-urban (Kavre) areas of Nepal to characterize community-level HEV 97 incidence. We enrolled geographically random sample of individuals aged 0-25 years 98 from the catchment areas of Kathmandu Medical College in Kathmandu and Dhulikhel 99 Hospital in Kavrepalanchok, Nepal from Feb 2019 to Apr 2021(15). Participants were 100 followed-up three times, approximately 3 months, 6 months, and 12 months after initial 101 enrollment and consent. During enrollment, relevant demographic data including age, 102 sex, socioeconomic status, were collected.

103 Sampling method

We employed a systematic random sampling strategy within our defined catchment areas. We randomly selected grid clusters, enumerated all households within each cluster, and then randomly selected participants based on age stratification using the groups 0-4, 5-9, 10-15, and 16-25 years. Our exclusion criteria were minimal to ensure a representative sample. We only excluded individuals who were not residents of the catchment area or did not fall within our specified age range at the time of the crosssectional survey.

111

113 Sample collection

- 114 At each visit, we collected capillary blood samples onto filter papers (TropBio FP 05-002-
- 115 12) using a finger-prick (dried blood spots; DBS). The samples were dried at room
- temperature for 24 hours then stored in individual plastic bags with desiccant at -20 C.

117 Laboratory Methods

We eluted the dried blood spots by submerging a single filled filter paper protrusion in 119 133 μ L of 1X PBS containing 0.05% Tween buffer and incubating overnight at 4°C. We 120 then centrifuged the tubes at 10,000xg and aliquoted the supernatant, considering this 121 DBS eluate as a 1:10 dilution.

122

We analyzed the samples using end-point ELISA with recomWell HEV IgG ELISA kits (Mikrogen Diagnostik), which evaluate immunoglobulin IgG against the recombinant HEV-ORF2 antigen. We read the ELISA plates at a wavelength of 450nm (with a reference wavelength of 690nm) using a Bio-Rad iMark ELISA plate reader.

127 Statistical Analysis

128

129 We fit 2-component Gaussian finite mixture models to determine an optimal cutoff value. 130 defined as the mean plus 3.5 standard deviations from the lower mixture component of 131 the log-transformed values (16). We then calculated seroprevalence as the percentage 132 of samples that were seropositive at each sampling interval. To describe how 133 seropositivity changes over age, we fit generalized additive models with a cubic spline for 134 age (17). We computed simultaneous confidence intervals using a parametric bootstrap 135 of the variance-covariance matrix of the fitted model parameters (18) (Mara, 2012). To 136 investigate variables associated with seropositivity, we used mixed-effect binomial logit 137 models with a random effect for community (19).

138

We calculated seroincidence, defined as the number of new seroconversions per 1000 person years, by dividing the number of individuals who seroconverted by the persontime at risk between measurements. We defined incident seroconversions as a change

in IgG across the seropositivity cutoff between sampling intervals. We used negative binomial mixed-effects regression models to explore the influence of various predictors on seroincidence, including area, gender, income level, water source, and frequency of eating outside, while adjusting for age. Each predictor was individually incorporated into the model, which also accounted for repeated measurements on the same individual across different visits and individual-level variability. An offset was introduced to adjust for person-time.

149

150 **Ethical Considerations**

The study protocol was reviewed and approved by the Nepal Health Research Council and Ethics Review Board of Dhulikhel Hospital and Stanford University. Written informed consent was obtained from all participants or their parents or legal guardians in the case of minors age <18. In addition, we obtained written assent from children between the ages of 15 and 17. The study was conducted following the principles of the Declaration of Helsinki.

157 **RESULTS**

158 We collected a total of 2513 dried blood samples from 923 study participants between 159 February 2019 to April 2021. Out of 923 study participants, 401 were from Kathmandu, 160 197 from Panauti (Kavre), 167 from Banepa (Kavre), 85 from Dhulikhel (Kavre) and 73 from Panchkhal (Kavre). The median age of participants was 11 years (Inter Quartile 161 162 Range [IQR]: 5.6 - 17) and 52.2% (482/923) were male. The median number of study 163 visits completed was 3 (IQR 2-3): 229/923: 65% (603/923) of participants had 3 or more 164 study visits while 18.2% 168/923 had just 1 study visit and 16.4% 152/923 had 2 study 165 visits (Table 1).

166

From the total of 2513 processed samples from 923 enrolled individuals, 106 samples (53 individuals) were seropositive for HEV (Figure 1). At the baseline visit, the crude seroprevalence was 4.8% (44/923) (Table 2). There were 9 incident seroconversions over

170 822.8 years of person-time, yielding a crude seroincidence rate of 10.9 (95% CI 5-20.8) 171 per 1000 person-years (Table 3). Both seroprevalence and seroincidence increased with 172 age. Among 0-5 year olds, the seroprevalence was 1.0% (2/199), increasing to 11.1% 173 (33/297) in the 15 to 25-year-old age group (p = 0.001; see Table 2 and Figure 2). The 174 seroincidence rate rose from 0 (95%CI: 0 - 32) per 1000 person-years for 0 to 5 year-olds 175 to 9.0 (95%CI: 1 - 32.4) for 5 to 10 year-olds, 14.0 (95%CI: 2.9 - 40.8) for 10 to 15 year-176 olds, and 14.8 (95%CI: 4.0 - 37.9) for 15 to 25 year-olds (Table 3). The age-adjusted 177 seroincidence was similar among females (10.3, 95% CI 2.8 - 26.3) compared to males 178 (11.6, 95% CI 3.8 - 27.2) (Table 3).

179

Individuals residing in households with a monthly income exceeding 30,000 Nepalese
rupees had a HEV seroprevalence of 4.3% (95% Cl 2.5 - 7.5) compared to 1.4% (95% Cl
0.7-3.0) for those in households earning below 30,000 Nepalese rupees (p = 0.003). The
age-adjusted seroincidence rate for the higher income group was 9.4 (95% Cl 3.0 - 30.0)
per 1000 person years, and 7.5 (95% Cl 2.4-23.3) for the lower income group.

185

186 HEV seroprevalence estimates did not vary markedly according to drinking water source, 187 with a seroprevalence of 2.9% (95% CI 1.3-6.3) among individuals whose primary 188 drinking water source was surface water, 3.6% (95% CI 1.9 - 6.6) for bottled water, 1.9% 189 (95%CI: 0.9-3.9) for municipal water, 2.3% (95%CI: 0.9-5.8) for ground water and 0.8% 190 (95%CI: 0.1-6.3) for a private water company. However, the HEV seroincidence rate 191 among individuals drinking surface water was higher than the other groups at 24.8 192 (95%CI: 9.9 - 61.5) per 1000 person-years compared to 5.6 (95% CI: 1.4-22.8) for 193 municipal water (p = 0.076). Of the 9 incident seroconversions, 5 reported drinking 194 surface water and of these 3 did not treat, 1 treated sometimes (<50% of the time) and 1 195 reported always treated water by boiling. However, when aggregated there were no 196 differences in HEV seroprevalence or seroincidence according to whether the household 197 treated their drinking water or not. Detailed seroprevalence and seroincidence are 198 provided in Tables 2 and 3.

199 HEV seroprevalence and seroincidence were not geographically uniform. The 200 seropositive cases are geospatially represented in Figure 2, revealing potential clusters

in both Kavre and Kathmandu districts. In Kavre district, seroprevalence was highest in
Banepa 3.5% (95% CI 95% CI: 1.7-7.3) and Panchkal 3.6% (95% CI 1.3-9.9). Within
Kathmandu, seropositive cases were centered in south-west of Tribhuvan airport, the one
incidence seroconversion was also in this area. In Kavre, seroconversions were centered
near Banepa (Figure 2).

206 **DISCUSSION**

This representative longitudinal serosurvey reveals ongoing HEV exposure in the Kathmandu Valley of Nepal. With a total of 2513 dried blood samples collected from 923 children and young adults, we observed a seroprevalence of 4.8% and a seroincidence rate of 10.9 seroconversions per 1000 person-years. These findings are consistent with the growing body of evidence suggesting that HEV is endemic in many parts of Nepal (10,11,13,14,20).

213

214 Unlike many enteric infections where the youngest are at the highest risk, our study found 215 the highest seroincidence among adolescents and young adults. Among those aged 15-216 25, 1 in 10 participants had evidence of HEV IgG exposure. This age group is particularly 217 significant as it encompasses women of childbearing age, where the risks of HEV 218 complications and mortality peak (3). This aligns with findings from other studies in 219 Bangladesh (6) and Nepal (20), which reported the highest HEV seroprevalence among 220 oldest enrolled subjects (70-74 in Bangladesh and 30-39 in Nepal). However, with 221 seroprevalence, these other studies were limited in their ability to disentangle age and 222 cohort effects. It's possible that seroprevalence among older ages reflected higher 223 periods of exposure in the past. In this study, by measuring incident seroconversions, we 224 were able to characterize a genuine higher risk of exposure with age.

225

The clustering of seropositive cases, especially around Banepa in Kavre and the southwestern region of Tribhuvan airport in Kathmandu, suggests localized outbreaks or common sources of exposure. The majority of incidence seroconversions in Kavre were within five kilometers of Banepa – where a high seroprevalence was observed at baseline. This may suggest propagative transmission from a potential previous outbreak. Such

clustering has been observed in other studies (21, 22), and underscores the importanceof targeted public health interventions in these regions.

233

234 Water source emerged as a significant factor influencing HEV seroincidence. Individuals 235 consuming surface water exhibited a notably higher seroincidence rate compared to 236 those relying on other water sources. This finding aligns with previous studies that have 237 identified contaminated water as a primary transmission route for HEV (21,22). The fact 238 that a majority of the incident seroconversions were observed in individuals who 239 consumed untreated or occasionally treated surface water further underscores the 240 importance of water quality in HEV exposure The spread of HEV to the environment might 241 pollute surface waters, which could act as the source of infection for both humans and 242 animals (23). Moreover, the occurrence of HEV in different water environments, even in 243 industrialized countries with sanitation and safe water supplies, has been documented, 244 emphasizing the need for continuous monitoring and intervention (23).

245

246 This study stands out as one of the few representative longitudinal serosurveys 247 specifically designed to capture incidence HEV seroconversions alongside HEV 248 seroprevalence. The variability in seroprevalence estimates across studies, even within 249 identical regions, is well-documented (24). Some of these discrepancies can be attributed 250 to methodologies that overlook the age-dependent nature of seroprevalence and/or 251 ignore antibody decay. Ignoring the waning of antibodies can lead to underestimations of 252 both seroprevalence and seroincidence, contingent on the rate and pattern of antibody 253 decay (25). In our study, the seroincidence derived from the age-dependent cross-254 sectional visit underestimated the true seroincidence by half. Moreover, seroincidence 255 measures are particularly valuable in identifying recent exposures that could amplify the 256 risk of infection and in pinpointing outbreaks. As an illustration, in our study while there 257 were only minor differences in seroprevalence based on water source, the seroincidence 258 of HEV among individuals consuming surface water was more than quadruple that of 259 those drinking municipal water.

261 Several limitations are worth noting. Firstly, our cohort did not include individuals above 262 25 years of age, restricting our ability to comment on the HEV burden in older age groups. 263 However, prior research has indicated that the most significant HEV burden is among 264 young adults(6,20). Our use of dried blood samples, though logistically advantageous, 265 might have increased the limit of detection our serological assays. A recent study 266 comparing HEV IgG responses in dried blood spots to venous blood reported a sensitivity 267 of 81% and a specificity of 97% (26). Given this reduced sensitivity, our findings may 268 underestimate the true HEV seroprevalence and seroincidence by up to 20%. 269 Additionally, our household sampling strategy could have inadvertently omitted migrant 270 populations and residents of informal settlements. Such populations, often faced with 271 subpar water, sanitation, and hygiene conditions, could potentially have a higher HEV 272 seropositivity rate, potentially further biasing our findings towards the null.

273

In summary, our study underscores the endemic nature of HEV in Nepal, revealing significant variations in seroprevalence and seroincidence based on age, water source, and geography. These insights emphasize the urgency for targeted public health strategies, especially in identified clusters, and spotlight the critical role of safe water practices in curtailing HEV incidence.

279

280 Acknowledgments

We gratefully acknowledge the study participants for their valuable time and interest in participating in the studies.

- 283
- 284
- 285
- 286
- 287

289 Tables

290 Table 1: Demographic Characteristics of enrolled individuals

	Banepa (N=167)	Dhulikhel (N=85)	Kathmandu (N=401)	Panauti (N=197)	Panchkhal (N=73)	Overall (N=923)
Age, in years						
Median (IQR)	10 (5.3 - 16)	9.5 (5.4 - 15)	12 (6.0 - 18)	11 (4.8 - 17)	10 (5.7 - 16)	11 (5.6 - 17)
Min/Max	1.2 - 27	1.1 - 25	0.90 - 27	0.90 - 27	1.3 - 24	0.90 - 27
Gender						
Female	82 (49.1%)	41 (48.2%)	183 (45.6%)	92 (46.7%)	33 (45.2%)	431 (46.7%)
Male	83 (49.7%)	43 (50.6%)	214 (53.4%)	102 (51.8%)	40 (54.8%)	482 (52.2%)
Missing	2 (1.2%)	1 (1.2%)	4 (1.0%)	3 (1.5%)	0 (0%)	10 (1.1%)
Number of study visits						
Median (IQR)	3.0 (3.0 - 4.0)	4.0 (3.0 - 4.0)	2.0 (1.0 - 3.0)	3.0 (2.0 - 4.0)	3.0 (3.0 - 3.0)	3.0 (2.0 - 3.0)
Min/Max	1.0 - 4.0	1.0 - 4.0	1.0 - 4.0	1.0 - 4.0	1.0 - 4.0	1.0 - 4.0
Monthly income, Nepalese rupees						
< 15000	11 (6.6%)	13 (15.3%)	34 (8.5%)	30 (15.2%)	12 (16.4%)	100 (10.8%)
15000-30000	47 (28.1%)	26 (30.6%)	116 (28.9%)	94 (47.7%)	29 (39.7%)	312 (33.8%)
30000-50000	49 (29.3%)	23 (27.1%)	119 (29.7%)	33 (16.8%)	13 (17.8%)	237 (25.7%)
>50000	17 (10.2%)	8 (9.4%)	55 (13.7%)	9 (4.6%)	6 (8.2%)	95 (10.3%)
Missing	43 (25.7%)	15 (17.6%)	77 (19.2%)	31 (15.7%)	13 (17.8%)	179 (19.4%)
Primary water source						
Municipal	88 (52.7%)	75 (88.2%)	116 (28.9%)	34 (17.3%)	13 (17.8%)	326 (35.3%)
Bottled	33 (19.8%)	0 (0%)	210 (52.4%)	0 (0%)	3 (4.1%)	246 (26.7%)
Ground	5 (3.0%)	2 (2.4%)	27 (6.7%)	55 (27.9%)	40 (54.8%)	129 (14.0%)
Private	4 (2.4%)	0 (0%)	36 (9.0%)	0 (0%)	0 (0%)	40 (4.3%)
Surface	35 (21.0%)	7 (8.2%)	7 (1.7%)	105 (53.3%)	17 (23.3%)	171 (18.5%)
Missing	2 (1.2%)	1 (1.2%)	5 (1.2%)	3 (1.5%)	0 (0%)	11 (1.2%)
Treat water before drinking						
No	65 (38.9%)	58 (68.2%)	190 (47.4%)	109 (55.3%)	50 (68.5%)	472 (51.1%)
Yes	100 (59.9%)	26 (30.6%)	206 (51.4%)	85 (43.1%)	23 (31.5%)	440 (47.7%)
Missing	2 (1.2%)	1 (1.2%)	5 (1.2%)	3 (1.5%)	0 (0%)	11 (1.2%)

297 Table 2: HEV Seroprevalence at baseline visit

levels	N()	N seropositive	Crude seroprevalence	Modeled seroprevalence (95% CI)	p value
Overall	923	44	4.8%	•	•
Age, categorical					
0-<5	199	2	1.0%	1.0% (0.3-3.9)	٠
5-<10	204	2	1.0%	1.0% (0.2-3.8)	0.980
10-<15	223	7	3.1%	3.1% (1.5-6.4)	0.151
15-25	297	33	11.1%	11.1% (8.0-15.2)	0.001
City/town*					
Banepa	167	10	6.0%	3.5% (1.7-7.3)	Ref
Dhulikhel	85	1	1.2%	0.7% (0.1-5.3)	0.139
Kathmandu	401	19	4.7%	2.3% (1.2-4.1)	0.279
Panauti	197	10	5.1%	2.7% (1.3-5.7)	0.583
Panchkhal	73	4	5.5%	3.6% (1.3-9.9)	0.973
Gender*					
Female	431	19	4.4%	2.4% (1.3-4.3)	Ref
Male	482	24	5.0%	2.7% (1.5-4.6)	0.725
Household monthl	y income	e, Nepalese rupees*			
<30000	412	10	2.4%	1.4% (0.7-2.9)	Ref
>30000	332	26	7.8%	4.3% (2.5-7.4)	0.003
Primary water sou	rce*				
Municipal	326	11	3.4%	1.9% (0.9-3.9)	Ref
Bottled	246	17	6.9%	3.6% (1.9-6.6)	0.119
Ground	129	5	3.9%	2.3% (0.9-5.8)	0.760
Private	40	1	2.5%	0.8% (0.1-6.3)	0.432
Surface	171	9	5.3%	2.9% (1.3-6.3)	0.368
Household treats	drinking	water*			
No	472	18	3.8%	2.1% (1.2-3.8)	Ref
Yes	440	25	5.7%	3.0% (1.7-5.1)	0.286
Note:					

²⁹⁸

*Mixed effect models adjusted for age with a random effect for city/town

300 Table 3: HEV Seroincidence

			Seroincidence rate per 100,000 person-years			
	Incident seroconversions	Person-years	Seroconversions/person-time	Modeled seroincidence*	p-value*	
Overall	9	822.8	10.9 (5.0-20.8)	10.3 (5.3-19.7)	•	
Age, categorica	I					
0-<5	0	115.2	0.0 (0.0-32.0)	0.00 (0.00-0.31)	•	
5-<10	2	222.7	9.0 (1.1-32.4)	8.73 (2.19-34.89)	Ref	
10-<15	3	214.7	14.0 (2.9-40.8)	13.46 (4.34-41.71)	0.019	
15-25	4	270.2	14.8 (4.0-37.9)	13.08 (4.91-34.84)	0.019	
City/town*						
Banepa	2	170.5	11.7 (1.4-42.4)	10.5 (2.6-42.6)	Ref	
Dhulikhel	2	106.9	18.7 (2.3-67.6)	17.1 (4.2-69.2)	0.625	
Kathmandu	1	247.6	4.0 (0.1-22.5)	3.4 (0.5-24.5)	0.355	
Panauti	4	208.9	19.1 (5.2-49.0)	16.8 (6.1-46.3)	0.588	
Panchkhal	0	89.0	0.0 (0.0-41.4)	•	1.000	
Gender*						
Female	4	389.8	10.3 (2.8-26.3)	8.9 (3.2-24.7)	Ref	
Male	5	429.4	11.6 (3.8-27.2)	10.3 (4.2-25.5)	0.831	
Household mon	thly income, Nepalese rupees	5*				
<30000	3	381.6	7.9 (1.6-23.0)	7.5 (2.4-23.3)	Ref	
>30000	3	283.5	10.6 (2.2-30.9)	9.4 (3.0-30.0)	0.779	
Primary water s	ource*					
Municipal	2	320.7	6.2 (0.8-22.5)	5.6 (1.4-22.8)	Ref	
Bottled	1	157.7	6.3 (0.2-35.3)	5.3 (0.7-38.2)	0.958	
Ground	1	138.0	7.2 (0.2-40.4)	6.5 (0.9-46.8)	0.903	
Private	0	26.1	0.0 (0.0-141.3)	•	1.000	
Surface	5	176.7	28.3 (9.2-66.0)	24.8 (10.0-61.5)	0.076	
Household treat	ts drinking water*					
No	5	442.4	11.3 (3.7-26.4)	10.1 (4.1-24.9)	Ref	
Yes	4	376.8	10.6 (2.9-27.2)	9.1 (3.3-25.3)	0.879	

Seroincidence rate per 100,000 person-years

³⁰¹

^{*}Mixed effect poisson model adjusted for age and repeated measures

303 Figures



304 Figure 1: Quantitative antibody responses by date and study site location

305

306





309

- 310 Figure 3: HEV Seroprevalence at baseline and prospective seroconversions across the
- 311 enrollment areas (Banepa, Panauti, Dhulikhel, Panchkhal: Kavre and Kathmandu) and
- 312 over the enrollment period of Feb 2019 to Apr 2021



314 **REFERENCES**

- Jindal A, Sarin SK. Epidemiology of liver failure in Asia-Pacific region. Liver
 International. 2022;42(9):2093–109.
- Kamar N, Bendall R, Legrand-Abravanel F, Xia NS, Ijaz S, Izopet J, et al. Hepatitis E.
 The Lancet. 2012 Jun 30;379(9835):2477–88.
- Navaneethan U, Al Mohajer M, Shata MT. Hepatitis E and pregnancy: understanding
 the pathogenesis. Liver International. 2008;28(9):1190–9.
- 4. Rein DB, Stevens GA, Theaker J, Wittenborn JS, Wiersma ST. The global burden of hepatitis E virus genotypes 1 and 2 in 2005. Hepatology. 2012;55(4):988–97.
- 5. Aggarwal R, Naik S. Epidemiology of hepatitis E: Current status. Journal of Gastroenterology and Hepatology. 2009;24(9):1484–93.
- Azman AS, Paul KK, Bhuiyan TR, Koyuncu A, Salje H, Qadri F, et al. Hepatitis E in
 Bangladesh: Insights From a National Serosurvey. The Journal of Infectious
 Diseases. 2021 Dec 15;224(Supplement_7):S805–12.
- Aiemjoy K, Seidman JC, Charles RC, Andrews JR. Seroepidemiology for Enteric
 Fever: Emerging Approaches and Opportunities. Open Forum Infectious Diseases.
 2023 May 1;10(Supplement_1):S21–5.
- Kmush BL, Yu H, Huang S, Zhang X, Wu T, Nelson KE, et al. Long-term Antibody
 Persistence After Hepatitis E Virus Infection and Vaccination in Dongtai, China. Open
 Forum Infect Dis. 2019 Mar 28;6(4):ofz144.
- Huang S, Zhang X, Jiang H, Yan Q, Ai X, Wang Y, et al. Profile of Acute Infectious
 Markers in Sporadic Hepatitis E. PLOS ONE. 2010 Oct 21;5(10):e13560.
- 10. Myint KSA, Endy TP, Shrestha MP, Shrestha SK, Vaughn DW, Innis BL, et al.
 Hepatitis E antibody kinetics in Nepalese patients☆. Transactions of The Royal
 Society of Tropical Medicine and Hygiene. 2006 Oct 1;100(10):938–41.
- 339 11. Shrestha S. Hepatitis E in Nepal. Kathmandu University medical journal (KUMJ). 2006
 340 Oct 1;4:530–44.
- 12. Izopet J, Labrique AB, Basnyat B, Dalton HR, Kmush B, Heaney CD, et al. Hepatitis
 E virus seroprevalence in three hyperendemic areas: Nepal, Bangladesh and
 southwest France. Journal of Clinical Virology. 2015 Sep 1;70:39–42.
- 344 13. Gupta BP, Lama TK, Adhikari A, Shrestha A, Rauniyar R, Sapkota B, et al. First report
 345 of hepatitis E virus viremia in healthy blood donors from Nepal. Virusdisease. 2016
 346 Sep;27(3):324–6.

- 347 14. Shrestha AC, Flower RLP, Seed CR, Rajkarnikar M, Shrestha SK, Thapa U, et al.
 348 Hepatitis E virus seroepidemiology: a post-earthquake study among blood donors in
 349 Nepal. BMC Infect Dis. 2016 Nov 25;16(1):707.
- 15. Andrews JR, Vaidya K, Saha S, Yousafzai MT, Hemlock C, Longley A, et al.
 Healthcare Utilization Patterns for Acute Febrile Illness in Bangladesh, Nepal, and
 Pakistan: Results from the Surveillance for Enteric Fever in Asia Project. Clinical
 Infectious Diseases. 2020 Nov 1;71(Supplement_3):S248–56.
- 16. Hens N, Shkedy Z, Aerts M, Faes C, Van Damme P, Beutels P. Modeling infectious
 disease parameters based on serological and social contact data: a modern statistical
 perspective. Vol. 63. Springer Science & Business Media; 2012.
- 357 17. Wood SN. Generalized additive models: an introduction with R. Chapman and
 358 Hall/CRC; 2006.
- 18. Marra G, Wood SN. Coverage properties of confidence intervals for generalized
 additive model components. Scandinavian Journal of Statistics. 2012;39(1):53–74.
- 361 19. Bates D, Mächler M, Bolker B, Walker S. Fitting Linear Mixed-Effects Models Using
 362 Ime4. Journal of Statistical Software. 2015 Oct 7;67:1–48.
- 20. Clayson ET, Shrestha MP, Vaughn DW, Snitbhan R, Shrestha KB, Longer CF, et al.
 Rates of hepatitis E virus infection and disease among adolescents and adults in
 Kathmandu, Nepal. J Infect Dis. 1997 Sep;176(3):763–6.
- 21. Owada K, Sarkar J, Rahman MK, Khan SA, Islam A, Hassan MM, et al.
 Epidemiological Profile of a Human Hepatitis E Virus Outbreak in 2018, Chattogram,
 Bangladesh. Trop Med Infect Dis. 2022 Aug 6;7(8):170.
- 22. Lenglet A, Ehlkes L, Taylor D, Fesselet JF, Nassariman JN, Ahamat A, et al. Does
 community-wide water chlorination reduce hepatitis E virus infections during an
 outbreak? A geospatial analysis of data from an outbreak in Am Timan, Chad (2016–
 2017). Journal of Water and Health. 2020 Jun 2;18(4):556–65.
- 373 23. Takuissu GR, Kenmoe S, Ndip L, Ebogo-Belobo JT, Kengne-Ndé C, Mbaga DS, et
 al. Hepatitis E Virus in Water Environments: A Systematic Review and Meta-analysis.
 375 Food Environ Virol. 2022 Sep 1;14(3):223–35.
- 376 24. Hartl J, Otto B, Madden RG, Webb G, Woolson KL, Kriston L, et al. Hepatitis E
 377 Seroprevalence in Europe: A Meta-Analysis. Viruses. 2016 Aug;8(8):211.
- 378 25. Teunis PFM, van Eijkeren JCH, de Graaf WF, Marinović AB, Kretzschmar MEE.
 379 Linking the seroresponse to infection to within-host heterogeneity in antibody
 380 production. Epidemics. 2016 Sep;16:33–9.

- 26. Øverbø J, Aziz A, Zaman K, Julin CH, Qadri F, Stene-Johansen K, et al. Stability and 381
- Feasibility of Dried Blood Spots for Hepatitis E Virus Serology in a Rural Setting. 382
- 383 Viruses. 2022 Nov;14(11):2525.